Catheter Precision, Inc.

Catheter Precision, Inc. filed an S-1 registration statement for the resale of 68,067,042 shares of common stock by various selling stockholders. These shares were issued through private placement financings, including convertible preferred stock and warrants, and acquisitions. The company will not receive any proceeds from these sales, and the offering carries a risk of substantial dilution for current shareholders.

Catheter Precision, Inc. filed an S-1 registration statement for the resale of 68,067,042 shares of common stock by selling stockholders. This follows the company's acquisition of Fly Flyte, Inc. and Ponderosa Air, LLC, establishing a new private aviation segment which generated approximately $0.2 million in Q1 2026 revenue. The company also completed several private placements, raising over $7.5 million in gross proceeds, and issued convertible preferred stock and warrants to related parties, with proceeds intended for debt repayment and potential restructuring of its legacy catheter business.

Catheter Precision, Inc. entered into a Securities Purchase Agreement on June 7, 2026, to acquire 2,941,176 shares of Volato Group, Inc. common stock for $1,000,000 in a private placement. In return, Volato Group agreed to provide Catheter Precision with freely tradeable equity securities of a third-party entity, which were valued at approximately $1,100,000 as of June 5, 2026. Additionally, a Registration Rights Agreement was executed, obligating Volato to file an S-3 registration statement for the resale of the purchased shares.

Catheter Precision, Inc. reported strong financial results for the first quarter of 2026, with revenue growing 200% year-over-year to $432,000. The company also announced the successful completion of the transformative Flyte acquisition, which established a new high-growth aviation platform and generated a $200,000 monthly revenue run rate within 22 days of post-acquisition operations. The net loss significantly reduced to $1.7 million from $4.0 million in Q1 2025, driven by revenue growth and operating discipline.

Catheter Precision, Inc. completed the acquisition of Fly Flyte, Inc. in Q1 2026, establishing a new private aviation segment alongside its cardiac electrophysiology business. The company reported a significant increase in total revenues to $432K for the quarter, up from $143K year-over-year, and an improved net loss of $1.69M compared to $4.05M in the prior year. Despite these improvements and recent financing activities, management issued a going concern warning due to recurring losses and negative operating cash flows.

Catheter Precision, Inc. (VTAK) filed an amendment to its 2025 Form 10-K to include detailed disclosures on related party transactions and director independence. Key transactions include the exchange of royalty rights with CEO David Jenkins and an affiliated entity for Series J Preferred Stock, resulting in a $2.6 million loss on debt extinguishment. The company also extended $1.5 million in related party notes payable and issued Series M warrants to these parties, while forming new subsidiaries with significant related party involvement.

Catheter Precision, Inc. announced the closing of its previously disclosed sale and issuance of Series C-2 Convertible Preferred Stock, raising $3.47 million in aggregate gross proceeds. The company issued 3,470 shares of the newly designated preferred stock, which is convertible into common stock at an initial price of $0.883 per share. This closing was contingent upon and followed the receipt of stockholder approval.